Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novartis Ag ADR
(NY:
NVS
)
115.97
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Sep 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Novartis Ag ADR
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
August 28, 2024
From
Lindy Biosciences
Via
Business Wire
The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
August 12, 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 12, 2024) - Investorideas.com, a go-to investing platform covering biotech and...
Via
Newsfile
Exposures
Product Safety
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
August 08, 2024
Via
Investor Brand Network
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
August 06, 2024
EQNX::TICKER_START (NYSE:ANVS),(NYSE:MRK),(NASDAQ:SNY),(NYSE:JNJ),(NYSE:NVS) EQNX::TICKER_END
Via
FinancialNewsMedia
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
August 06, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
July 30, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Novartis AG (NYSE: NVS) Highlighted for Surprising Price Action
April 04, 2024
Via
Investor Brand Network
Novartis AG (NYSE: NVS) Records 52-Week High Friday Morning
January 05, 2024
Via
Investor Brand Network
Pharma Leader Beats on Earnings, But Shares Fall
July 19, 2024
Novartis released its Q2 financial results. It beat expectations on EPS and revenue. However, shares fell, possibly due to bad news on one upcoming drug.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Leigh Burgess, CEO & Founder Bold Industries Group, Announces Pre-Sale of New Book: Be BOLD Today
June 04, 2024
Via
Get News
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
May 08, 2024
Via
AB Newswire
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
April 11, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
March 14, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END
Via
FinancialNewsMedia
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
February 27, 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Via
Newsfile
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
February 14, 2024
From
Erasca, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Appoints Liat Halpert as Head of Business Development, Sales
February 13, 2024
Via
Investor Brand Network
Insufficient self-sufficiency of raw materials in Japan
January 08, 2024
Via
AB Newswire
Topics
Supply Chain
Exposures
Supply Chain
Voyager Therapeutics stock pops 30% on deal with Novartis
January 08, 2024
Voyager Therapeutics Inc. (NASDAQ: VYGR) is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took
Via
MarketBeat
2 low-priced gene therapy stocks to speculate on
January 08, 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe
Via
MarketBeat
Exposures
Product Safety
2 gene-editing stocks reshaping hereditary disease treatments
January 02, 2024
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal
Via
MarketBeat
A Comprehensive Study Exploring Breast Cancer Treatment Market : Key Players Gilead Sciences, Astellas, Celgene
December 07, 2023
Get an extensive Breast Cancer Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.
Via
SBWire
Allergy Treatment Market Know Faster Growing Segments Now: Akorn, Pfizer, Novartis, Mylan N.V
November 30, 2023
Global Allergy Treatment Market Breakdown by Application (Hospitals, Specialty Clinics, Homecare, Others) by Type (Eye Allergy, Food Allergy, Skin Allergy, Asthma, Rhinitis, Others) by Treatment...
Via
SBWire
Anti-Inflammatory Drugs Market Boosting the Growth Worldwide 2030
November 29, 2023
Get Anti-inflammatory Drugs Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis.
Via
SBWire
Gene Therapy Market Research: Exploring Market Size, Business Growth, Career Prospects, Industry Trends, and Projections for 2028
November 27, 2023
Northbrook, IL 60062 -- (SBWIRE) -- 11/27/2023 -- In May 2022, Novartis AG (Switzerland) received US FDA approval for KYMRIAH (Tisagenlecleucel) for a third indication, including relapsed or refractory...
Via
SBWire
Exposures
Product Safety
2 overlooked stocks that crushed earnings but traded lower
November 20, 2023
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results
Via
MarketBeat
Exposures
Product Safety
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
November 14, 2023
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END
Via
FinancialNewsMedia
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
November 01, 2023
Via
Investor Brand Network
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
November 01, 2023
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:JNJ),(NYSE:SNY),(NASDAQ:AMGN),(NYSE:NVS) EQNX::TICKER_END
Via
FinancialNewsMedia
Nano Pharmaceutical Market Next Big Move: Major Giants Abbott Laboratories, Bayer AG, Novartis AG, GlaxoSmithKline
October 24, 2023
According to HTF Market Intelligence, the Global Nano Pharmaceutical market is segmented by Application (Oncology, Cardiovascular/Physiology, Antiinflammatory/Immunology, Neurology, Anti-Infective,...
Via
SBWire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.